Esketamine – Kodiac biolabs

Plain-language summaryIntrigue 82 / 100

Esketamine, sold as Spravato, is the S-enantiomer of ketamine purified out as a single isomer. Approved in 2019 as an intranasal spray for treatment-resistant depression. About twice as potent as racemic ketamine at NMDA receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

61/100

FDA-approved rapid antidepressant with live mechanistic debate around stereochemistry and HNK metabolite signal

Look, esketamine occupies a strange position in a research library. It’s an FDA-approved Schedule III drug with a real REMS program, multiple Phase 3 RCTs behind it, and the only formal regulatory endorsement in the rapid-acting antidepressant class. That’s legitimate standing. But the question for bench investigators is whether the compound is still generating new science, or whether the interesting questions have migrated somewhere downstream and esketamine is now mostly a clinical asset with a closed mechanistic story. The honest answer is: it’s somewhere in between.

The still-live science centers on mechanism. Whether the antidepressant effect comes from direct NMDA channel block, downstream AMPA potentiation, or the (2R,6R)-hydroxynorketamine metabolite that may bypass NMDA entirely is genuinely unresolved. The Zanos et al. 2016 Nature paper on HNK sparked a real fight that hasnt been settled, and esketamine is relevant to that fight precisely because its stereospecificity lets investigators parse contributions that racemic ketamine muddles. If you’re working on rapid-antidepressant mechanism, enantiomeric comparisons between S- and R-ketamine give you a probe you can’t replicate with the racemate.

The differentiation case is complicated. Esketamine has the FDA stamp and standardized intranasal delivery, but IV racemic ketamine is still widely used off-label, often preferred clinically because of cost and dosing flexibility. More pressingly, the emerging R-ketamine story from the Hashimoto lab argues that the R-enantiomer may produce antidepressant effects without dissociation, which if confirmed would directly challenge esketamine’s clinical position and make the stereochemistry question more urgent for research programs, not less.

Evidence quality is solid. The TRANSFORM and SUSTAIN trial programs gave esketamine multiple Phase 3 wins, and real-world post-approval data is accumulating. The methodological criticisms are legitimate, the open-label responder enrichment designs took pointed criticism at the FDA advisory committee level, but the compound cleared the bar and is being used on patients with treatment-resistant depression. That’s real translational signal, specifically in a population where alternatives are genuinely exhausted.

Where the score pulls back is novelty and conditional bench utility. Ketamine pharmacology has been in the literature since the 1960s. If your research question is not specifically about stereochemistry, enantiomeric dissociation, or NMDA-independent rapid antidepressant pathways, esketamine doesn’t open doors the racemate hasn’t already touched. What we like: unresolved mechanistic questions, enantiomeric probe specificity, FDA-validated clinical effect in a hard population. What we dont like: REMS overhead for research access, and the sense that the frontier has moved toward HNK and downstream plasticity targets rather than the parent compound itself.

Novelty: 40
Mechanism promise: 65
In-category differentiation: 58
Evidence quality: 70
Translational signal: 75
Research bench value: 65

Rationale Novelty is limited by decades of ketamine literature, but esketamine earns real points for FDA approval, well-documented Phase 3 evidence, and the genuinely unresolved mechanistic fight over whether the antidepressant signal traces to NMDA block, AMPA potentiation, or the (2R,6R)-HNK metabolite. Score reflects an established compound with meaningful bench utility for stereochemistry and rapid-antidepressant mechanism research, pulled back by REMS overhead, aging underlying pharmacology, and a research frontier that is visibly migrating toward metabolite biology.

S-enantiomer NMDA antagonist

The (S)-enantiomer of ketamine, FDA-approved as Spravato (intranasal) for treatment-resistant depression.

Abstract

Esketamine (Spravato; CAS 33643-46-8) is the (S)-enantiomer of ketamine, FDA-approved in 2019 as an intranasal formulation for treatment-resistant depression and as adjunctive treatment for major depressive disorder with acute suicidal ideation (2020). The (S)-enantiomer carries higher NMDA receptor affinity than the (R)-enantiomer; the racemic ketamine is approximately 60 percent (S)-enantiomer activity. Pharmacokinetics: intranasal bioavailability ~48 percent; plasma half-life 7 to 12 hours. Approved doses are 56 to 84 mg intranasal twice weekly initially, tapering. Schedule III. REMS distribution program due to dissociation and abuse risk.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-171Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.